Amarin Corporation Plc Sponsored ADR Stock

$0.44

1.11% day before yesterday

Nasdaq, Dec 27, 09:45 pm CET

ISIN

US0231112063

Symbol

AMRN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Amarin Corporation Plc Sponsored ADR Stock price

$0.45

-21.10 97.92% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.00 0.16%

ISIN

US0231112063

Symbol

AMRN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$184.25m
Enterprise Value	$-113.79m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	6.17
EV/Sales (TTM) EV/Sales	-0.47
P/S ratio (TTM) P/S ratio	0.76
P/B ratio (TTM) P/B ratio	0.35
Revenue growth (TTM) Revenue growth	-25.21%
Revenue (TTM) Revenue	$242.15m
EBIT (operating result TTM) EBIT	$-44.17m
Free Cash Flow (TTM) Free Cash Flow	$-18.44m
Cash position	$306.26m
EPS (TTM) EPS	$-0.10
P/E forward	negative
P/S forward	0.91
EV/Sales forward	negative
Short interest	4.42%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Amarin Corporation Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Amarin Corporation Plc Sponsored ADR forecast:

1x Hold

33%

2x Sell

67%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Amarin Corporation Plc Sponsored ADR forecast:

Hold

33%

Sell

67%

Analyst Estimates with Stock Price Targets

Financial data from Amarin Corporation Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	242 242	25% 25% 100%
- Direct Costs	109 109	24% 24% 45%
Gross Profit	134 134	27% 27% 55%
- Selling and Administrative Expenses	157 157	29% 29% 65%
- Research and Development Expense	18 18	5% 5% 7%
EBITDA	-41 -41	30% 30% -17%
- Depreciation and Amortization	3.02 3.02	1% 1% 1%
EBIT (Operating Income) EBIT	-44 -44	29% 29% -18%
Net Profit	-40 -40	25% 25% -16%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Amarin Corporation Plc Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

13 days ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients 1 -- -- Italy is the Third EU5 Market to Grant National Reimbursement; Ninth National Reimbursement for VAZKEPA® Overall in Europe --

Neutral

GlobeNewsWire

●

16 days ago

Amarin Appoints Peter Fishman Chief Financial Officer

Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company

Neutral

Seeking Alpha

●

about 2 months ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Amarin Corporation plc (NASDAQ:AMRN ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conf...

More Amarin Corporation Plc Sponsored ADR News

Company Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Head office	United Kingdom
CEO	Aaron Berg
Employees	275
Founded	1989
Website	www.amarincorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now